Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-11-14
2006-11-14
Saoud, Christine J. (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200, C530S350000
Reexamination Certificate
active
07135454
ABSTRACT:
Disclosed herein are compositions and methods for the treatment or prevention of neurological disorders. Also disclosed are compositions and methods for the treatment or prevention of skin pathologies. The invention further discloses compositions and methods for the modulation of acetylcholine receptor activity. Antibodies generated against SLURP-1 and related proteins are also included.
REFERENCES:
patent: 5298604 (1994-03-01), Sloane
patent: 5908827 (1999-06-01), Sirna
patent: 0 675 956 (1995-10-01), None
patent: 0 895 478 (1999-02-01), None
patent: 1 093 380 (2001-04-01), None
patent: WO 98/56810 (1998-12-01), None
Arredondo et al. (2002). Central role of alpha7 nicotinic receptor in differentiation of the stratified epithelium. The Journal of Cell Biology. 159(2):325-336.
Miller, G. (2002). Breaking down barriers. Science 297:1116-1118.
Pettit et al. (1998). The development of site-specific drug-delivery systems for protein and peptide biopharmaceuticals. Trends Biotechnol 16: 343-349.
Freedman et al. (1997). Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc. Natl. Acad. Sci. USA 94:587-592.
Guan et al. (1999). Decreased protein level of nicotinic α7 subunit in the frontal cortex from schizophrenic brain. NeuroReoort. 10:1779-1782.
Freedman et al. (1995). Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol. Psychiatry. 38:22-33.
Freedman et al. (2000). The α7-nicotinic acetylcholine receptor and the pathology of hippocampal interneurons in schizophrenia. Journal of Chemical Neuroanatomy. 20:299-306.
Gault et al. (2003). Comparison of polymorphisms in the α7 nicotinic receptor gene and its partial duplication in schizophrenic and control subjects. American Journal of Medical Genetics Part B (Neuropsychiatric Genetics). 123B:39-49.
Simosky et al. (2003). Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism. Psychopharmacology. 165:386-396.
Simosky et al. (2001). Intragastric DMXB-A, an α7 nicotinic agonist, improves deficient sensory inhibition of DBA/2 mice. Biol. Psychiatry. 50:493-500.
Stevens et al. (1998). Selective α7-nicotinic agonists normalize inhibition of auditory response in DBA mice. Psychopharmacology. 136:320-327.
O'Neill et al. (2003). DMXB, an α7 nicotinic agonist, normalizes auditory gating in isolation-reared rats. Psychopharmacology. 169:332-339.
Grantham et al. (2003). Modulation of alpha 7 nicotinic receptors as a strategy for therapy in schizophrenia. Schizophrenia Research. 60(1), Suppl. 1:107.
Martin et al. (2004). Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology. 174:54-64.
Adermann, et al.,Protein Sci.,8:810-819 (1999).
Blasi, et al.,Nat. Rev. Mol. Cell Biol.,3(12):932-943 (2002).
Borovikova, et al.,Nature, 405:458-462 (2000).
Brakenhoff et al.,J. Cell Biol.,129(6):1677-1689 (1995).
Casey, et al.,Blood, 84(4):1151-1156 (1994).
Chimienti, et al.,Hum. Mol. Genet.,12(22)3017-3024 (2003).
Eckl, et al.,Hum. Genet.,112:50-56 (2003).
Elias, et al.,J. Invest. Dermatol.,119:1128-1136 (2002).
Fischer, et al.,Eur. J. Hum. Genet.,6:542-547 (1998).
Fischer, et al.,Hum. Mol. Genet.,10(8):875-880 (2001).
Grando, et al.,J. Invest. Dermatol.,105:774-781 (1995).
Grando, et al.,Curr. Opin. Dermatol.,4:262-268 (1997).
Grando, S.A.,J. Invest. Dermatol. Symp. Proc.,2:41-48 (1997).
Horie, et al.,Genomics, 53:365-368 (1998).
Ibenez-Tallon, et al.,Neuron, 33(6):893-903 (2002).
Jacobi, et al.,Am. J. Pathol.,161(1):97-104 (2002).
Kini, R. M.,Clin. Exp. Pharmacol. Physiol.,29(9):815-822 (2002).
Köck, et al.,J. Exp. Med.,172:1609-1614 (1990).
Kondo, et al.,Eur. J. Immunol.,27:1713-1718 (1997).
Mastrangeli, et al.,Eur. J. Dermatol.,13(6):560-570 (2003).
Menon, et al.,J. Invest. Dermatol.,84(6):508-512 (1985).
Miwa, et al.,Neuron, 23:105-114 (1999).
Montuori, et al.,J. Biol. Chem.,277(49):46932-46939 (2002).
Palfree, R. G. E.,Immunol. Today, 12(5):170 (1991).
Ploug, et al.,J. Biol. Chem.,268(23):17539-17546 (1993).
Ploug, et al.,FEBS Lett.,349:163-168 (1994).
Reiter, et al.,Proc. Natl. Acad. Sci. USA, 95:1735-1740 (1998).
Schrijvers, et al.,Exp. Cell Res.,196:264-269 (1991).
Shan, et al.,J. Immunol.,160:197-208 (1998).
Tone, et al.,J. Mol. Biol.,227:971-976 (1992).
Tsuji, et al.,Genomics, 81:26-33 (2003).
Wang, et al.,Nature, 421:384-388 (2003).
Ward, et al.,J. Invest. Dermatol.,120:96-98 (2003).
Bertrand Daniel
Chimienti Fabrice
Hogg Ronald
Hohl Daniel
Huber Marcel
Applied Research Systems ARS Holding N.V.
Elrifi Ivor R.
Lockard Jon M.
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
Saoud Christine J.
LandOfFree
Use of SLURP-1 compositions for treating schizophrenia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of SLURP-1 compositions for treating schizophrenia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of SLURP-1 compositions for treating schizophrenia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3691415